CTNNB1 and hepatocellular carcinoma: To investigate the basis of the observed heterogeneous response, we first utilized the 10× Visium platform to perform unbiased spatial transcriptomics on an LNP-CTRL treated β-M HCC (β-M Control), 2 LNP-CTNNB1 treated β-M HCC showing minimal/poor response (β-M NR-1; β-M NR-2), and an LNP-CTNNB1 treated β-M HCC showing response (β-M R-1).